Why Does US Healthcare Cost More Without Making Americans Healthier?

The United States expends nearly double per person on medical care compared with the average advanced economy, consuming more than 17% of gross domestic product. Despite this capital allocation, American population health consistently lags OECD peers in life expectancy, maternal mortality, and chronic metabolic disease incidence. Conventional policy debate reduces this divergence either to gaps in insurance coverage or to the necessary price of clinical innovation.

Mainstream health economists often contend that higher spending merely reflects rapid domestic adoption of advanced technologies, novel biologics, and higher clinical labor compensation. Yet cross-national data shows that greater procedural volume and capital expenditure have failed to generate proportionate gains in life expectancy or functional vitality. The problem is fundamentally structural, driven by an institutional apparatus organized around financial rent extraction and a physical environment engineered for metabolic decline.

This analysis is top level by design. Thousands of pages have been written on this, so if you are curious about this topic, I encourage you to go down the rabbit hole and dig into all of these issues.

The Architecture of Financial Extraction

High medical expenditure in the United States does not purchase superior clinical results. It finances an elaborate network of supply-chain intermediaries, institutional billing arbitrage, and the public absorption of private liabilities.

For non-elderly working adults, routine medical interaction centers primarily on access to generic pharmaceuticals. In a competitive marketplace, off-patent medications function as standard manufactured commodities, with marginal unit production costs measured in pennies. Essential off-patent antibiotics, including amoxicillin and azithromycin, require mere cents per dose to formulate and package.

Yet an opaque layer of pharmacy benefit managers, wholesale distributors, and group purchasing organizations sits between the factory floor and the patient. Federal Trade Commission inquiries into intermediary practices reveal that the dominant pharmacy benefit managers routinely mark up generic and specialty medications by hundreds to thousands of percent over the National Average Drug Acquisition Cost. Independent analysis published in Annals of Internal Medicine assessing direct, transparent manufacturer pricing models demonstrated that Medicare Part D spent over $8 billion on generic drugs that could have been obtained for $4.5 billion under transparent, direct-cost arrangements. Under this arrangement, the primary care physician operates less as a clinical counselor and more as an institutional toll collector whose authorization is legally required to release cheap chemical compounds into a high-margin supply chain.

Provider networks have consolidated into powerful regional hospital organizations, enabling extensive billing arbitrage through Hospital Outpatient Department classifications. Routine imaging procedures, diagnostic colonoscopies, and minor therapies that are delivered safely in private offices at low cost are billed inside hospital systems at inflated multiples through institutional facility fees. Hospital trade associations defend this practice by arguing that acute facilities carry massive overhead costs, including continuous emergency department readiness, intensive trauma capacity, and uncompensated charity care. However, the Medicare Payment Advisory Commission has repeatedly reported that identical clinical services cost Medicare significantly more in hospital outpatient departments than in independent physician practices, paying roughly $741 for a routine injection in an outpatient hospital department compared with $256 in an independent clinic. Commercial claims data from the Health Care Cost Institute indicates that implementing site-neutral payment caps across routine outpatient services would save private purchasers and patients more than $10 billion each year.

Acute-care hospital operating margins routinely hover between 1% and 4%. This structural vulnerability provides hospital systems with substantial political leverage whenever operating margins face pressure. Provider lobbies routinely secure upward payment adjustments from the Centers for Medicare & Medicaid Services. Because commercial private insurers negotiate contracts indexed against Medicare fee schedules, federal rate increases establish a higher baseline floor across the broader marketplace. Instead of forcing internal cost rationalization, the public sector guarantees institutional margins, generating an upward pricing ratchet that is ultimately funded through higher employer and worker premiums.

The underlying risk model of American private health insurance relies on a major actuarial asymmetry. Kaiser Family Foundation spending distributions demonstrate that the bottom 50% of the population accounts for only 3% of total national health expenditure, averaging under $500 per person annually. Private commercial insurers collect steady premiums across a four-decade working career while bearing minimal clinical liabilities. Significant chronic disease, joint deterioration, and cardiovascular interventions concentrate heavily in the immediate years prior to retirement. Federal expenditure data indicates that adults aged 55 and older consume roughly 57% of total national healthcare expenditures. Private payers absorb these costs during a narrow window between ages 61 and 64, only to transfer the entire high-cost population onto Medicare at age 65.

Lowering the Medicare eligibility threshold to age 58 or 60 could be a notable structural policy option. Critics argue that shifting older workers into the public program would accelerate the insolvency of the Medicare Part A trust fund and add new federal obligations. Yet removing this volatile, high-cost demographic from the private commercial risk pool would reduce employer group premiums by double digits, trading private administrative overhead for a transparent, broader public payroll assessment.

The Health Deficit: Sick Care and Metabolic Collapse

The upward climb of medical expenditure runs parallel to a sustained deterioration in baseline physical health. American healthcare is organized as an interventionist repair shop, designed to bill for high-cost procedures only after extensive vascular and cellular damage has already occurred.

The divergence in American metabolic health accelerated after 1980. Longitudinal tracking from the Centers for Disease Control and the National Health and Nutrition Examination Survey shows that adult obesity rates remained flat between 13% and 15% from 1960 to 1980. Following the release of the 1980 Dietary Guidelines for Americans, which discouraged dietary fats in favor of grain-based carbohydrates, adult obesity began a continuous upward trajectory, crossing 30% by 2000 and exceeding 42% in recent surveys. Diagnosed Type 2 diabetes expanded four-fold over the same period, increasing from approximately 5.5 million Americans to more than 29 million today.

Industrial food processors met the mandate to eliminate fat by adding significant quantities of refined sugar, chemical acidifiers, and sodium to maintain product texture and taste. This period coincided with the corporate acquisition of major consumer packaged goods firms by legacy tobacco companies during the late 1980s. Research from the University of Kansas published in Addiction demonstrated that food brands owned by tobacco conglomerates between 1988 and 2001 were 29% more likely to be formulated as fat-and-sodium hyper-palatable foods, and 80% more likely to be carbohydrate-and-sodium hyper-palatable foods, than products from independent competitors. These formulations were intentionally designed to stimulate dopamine pathways, override natural hormonal satiety signals, and encourage chronic overconsumption.

While social factors like occupational stress and sleep deprivation undeniably contribute to poor health, this dietary environment is reinforced by physical infrastructure that systematically limits daily movement. A global mobility study led by Stanford University analyzing smartphone telemetry across 700,000 subjects revealed that the average American logs approximately 4,700 steps per day, trailing peer economies such as Japan and Western European nations where baseline daily activity averages 5,500 to 6,000 steps. The researchers established that car-dependent environments generate pronounced activity inequality, which correlates directly with higher population-level obesity. When daily physical activity is eliminated from standard routines and whole foods carry a distinct price and convenience penalty compared to shelf-stable processed goods, chronic metabolic decline becomes an inevitable structural outcome.

Capital Misallocation and the Bottom Line

The failure of American healthcare is not an innovation bottleneck, but an institutional alignment failure. Capital is concentrated downstream in managing chronic metabolic decline and organ damage, while public policy protects the operating spreads of supply-chain intermediaries and regional hospital monopolies. Until statutory reforms mandate site-neutral pricing, rein in intermediary margins, and confront the incentives embedded within the commercial food system, per capita expenditures will continue to rise while overall population resilience declines. There is a multi-billion dollar opportunity to disrupt a highly-regulated status quo industry.